Physician profile
Rosa L Arancibia
NPI 1205125846
$4,486.90
in general payments reported to CMS, 2019-2025
23 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2020: $62.71 · 2021: $394 · 2022: $825 · 2023: $1,873 · 2024: $365 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744 · Travel and Lodging: $1,247 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.12 |
| Travel and Lodging | $1,246.79 |
| Education | $114.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,345.23 | 2023 | Da Vinci Surgical System |
| Ethicon INC. | $784.26 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $376.23 | 2023-2025 | Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.84 | 2019-2025 | Jascayd, Ofev, Spiriva |
| Boston Scientific Corporation | $339.16 | 2021 | |
| Glaxosmithkline, LLC. | $217.89 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Ani Pharmaceuticals, INC. | $213.93 | 2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $185.54 | 2022-2024 | Opsumit, Uptravi |
| Galvanize Therapeutics, INC | $138.94 | 2023 | Aliya System |
| Allergan, INC. | $83.76 | 2019 | |
| Insmed, INC. | $70.73 | 2025 | Arikayce, Brinsupri |
| Inogen, INC. | $61.53 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Merck Sharp & Dohme LLC | $58.91 | 2021-2025 | Zerbaxa |
| United Therapeutics Corporation | $55.99 | 2021-2024 | Remodulin, Tyvaso |
| Abbvie INC. | $29.71 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $26.77 | 2025 | |
| Lilly USA, LLC | $25.09 | 2025 | Zepbound |
| Mallinckrodt Hospital Products INC. | $24.79 | 2025 | Acthar |
| Amgen INC. | $23.82 | 2025 | Tezspire |
| Janssen Pharmaceuticals, INC | $19.21 | 2020 | |
| Gilead Sciences, INC. | $15.83 | 2025 | Veklury |
| Electromed, INC. | $15.06 | 2025 | Smartvest |
| Advanced Respiratory, INC | $14.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa Arancibia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.